Partner Investment Management L.P. bought a new position in shares of Inogen Inc (NASDAQ:INGN) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,856 shares of the medical technology company’s stock, valued at approximately $453,000.
Other institutional investors have also bought and sold shares of the company. Invictus RG bought a new stake in shares of Inogen in the third quarter valued at about $650,000. Renaissance Technologies LLC lifted its stake in Inogen by 18.7% during the third quarter. Renaissance Technologies LLC now owns 367,900 shares of the medical technology company’s stock worth $89,812,000 after purchasing an additional 58,086 shares during the period. Mutual of America Capital Management LLC lifted its stake in Inogen by 23,339.1% during the third quarter. Mutual of America Capital Management LLC now owns 15,001 shares of the medical technology company’s stock worth $3,662,000 after purchasing an additional 14,937 shares during the period. Kepos Capital LP bought a new position in Inogen during the third quarter worth about $1,324,000. Finally, JPMorgan Chase & Co. lifted its stake in Inogen by 17.5% during the third quarter. JPMorgan Chase & Co. now owns 79,902 shares of the medical technology company’s stock worth $19,505,000 after purchasing an additional 11,928 shares during the period. 98.65% of the stock is currently owned by hedge funds and other institutional investors.
In other news, Director Ray Benjamin M. Anderson sold 1,000 shares of Inogen stock in a transaction that occurred on Monday, October 1st. The shares were sold at an average price of $246.22, for a total value of $246,220.00. Following the completion of the transaction, the director now owns 1,989 shares in the company, valued at $489,731.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Raymond Huggenberger sold 10,500 shares of Inogen stock in a transaction that occurred on Friday, September 14th. The shares were sold at an average price of $282.57, for a total transaction of $2,966,985.00. Following the completion of the transaction, the director now owns 8,797 shares of the company’s stock, valued at approximately $2,485,768.29. The disclosure for this sale can be found here. Insiders sold 32,000 shares of company stock valued at $7,580,605 in the last quarter. 5.29% of the stock is currently owned by corporate insiders.
Inogen (NASDAQ:INGN) last announced its quarterly earnings results on Tuesday, November 6th. The medical technology company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.52 by $0.21. The firm had revenue of $95.29 million during the quarter, compared to analysts’ expectations of $90.94 million. Inogen had a net margin of 12.28% and a return on equity of 18.91%. The company’s revenue for the quarter was up 38.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.33 earnings per share. On average, equities analysts expect that Inogen Inc will post 2.1 EPS for the current year.
A number of research analysts have commented on the stock. BidaskClub upgraded shares of Inogen from a “strong sell” rating to a “sell” rating in a research note on Wednesday, November 28th. Needham & Company LLC raised their price target on shares of Inogen to $280.00 and gave the stock a “strong-buy” rating in a research note on Monday, November 26th. ValuEngine cut shares of Inogen from a “buy” rating to a “hold” rating in a research note on Wednesday, November 7th. Finally, Zacks Investment Research upgraded shares of Inogen from a “hold” rating to a “buy” rating and set a $290.00 price target for the company in a research note on Thursday, September 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $244.67.
ILLEGAL ACTIVITY WARNING: “Partner Investment Management L.P. Invests $453,000 in Inogen Inc (INGN) Stock” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://sportsperspectives.com/2018/12/06/partner-investment-management-l-p-invests-453000-in-inogen-inc-ingn-stock.html.
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Further Reading: Buyback
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.